<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Recursion Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/recursion-pharmaceuticals-inc</link>
<description>Latest news and press releases for Recursion Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 31 Mar 2026 13:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/recursion-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835bb6878dffbe2df116514.webp</url>
<title>Recursion Pharmaceuticals Inc</title>
<link>https://6ix.com/company/recursion-pharmaceuticals-inc</link>
</image>
<item>
<title>Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform</title>
<link>https://6ix.com/company/recursion-pharmaceuticals-inc/news/recursion-expands-strategic-partnership-with-citeline-to-advance-its-ai-enabled-clintech-platform</link>
<guid isPermaLink="true">https://6ix.com/company/recursion-pharmaceuticals-inc/news/recursion-expands-strategic-partnership-with-citeline-to-advance-its-ai-enabled-clintech-platform</guid>
<pubDate>Tue, 31 Mar 2026 13:00:00 GMT</pubDate>
<description>NEW YORK and SALT LAKE CITY, March 31, 2026 (GLOBE NEWSWIRE) -- Citeline, a leader in clinical solutions for the life sciences industry, today announced an expanded strategic partnership with Recursion (NASDAQ: RXRX), a leading tech-bio company decoding biology through advanced data science and automation. Recursion’s end-to-end platform is designed to connect discovery through development by integrating proprietary multimodal datasets, purpose-built AI models, and experimental biology. The addi</description>
</item>
<item>
<title>Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer</title>
<link>https://6ix.com/company/recursion-pharmaceuticals-inc/news/recursion-announces-vicki-goodman-md-as-incoming-chief-medical-officer</link>
<guid isPermaLink="true">https://6ix.com/company/recursion-pharmaceuticals-inc/news/recursion-announces-vicki-goodman-md-as-incoming-chief-medical-officer</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>Salt Lake City, UT, March 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically</description>
</item>
<item>
<title>PacBio Announces the Appointment of Chris Gibson to the Board of Directors</title>
<link>https://6ix.com/company/recursion-pharmaceuticals-inc/news/pacbio-announces-the-appointment-of-chris-gibson-to-the-board-of-directors-32</link>
<guid isPermaLink="true">https://6ix.com/company/recursion-pharmaceuticals-inc/news/pacbio-announces-the-appointment-of-chris-gibson-to-the-board-of-directors-32</guid>
<pubDate>Thu, 05 Mar 2026 13:30:00 GMT</pubDate>
<description>Proven experience in leveraging AI in biology will strengthen the board of directors as PacBio develops data tools to maximize the power of HiFi sequencingMENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio’s Board of Directors. Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ: RXRX), a cli</description>
</item>
<item>
<title>Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/recursion-pharmaceuticals-inc/news/recursion-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/recursion-pharmaceuticals-inc/news/recursion-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Wed, 25 Feb 2026 11:30:00 GMT</pubDate>
<description>Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinical and preclinical programs advancing with defined milestonesAchieved fifth program milestone with Sanofi, totaling $134 million in payments to date; five Recursion discovery program packages have been accepted to date, establishing a growing joint portfolio of novel AI-driven small molecules for imm</description>
</item>
<item>
<title>Recursion To Be Featured in HighRes’ Lightning Talk at NVIDIA GTC</title>
<link>https://6ix.com/company/recursion-pharmaceuticals-inc/news/recursion-to-be-featured-in-highres-lightning-talk-at-nvidia-gtc</link>
<guid isPermaLink="true">https://6ix.com/company/recursion-pharmaceuticals-inc/news/recursion-to-be-featured-in-highres-lightning-talk-at-nvidia-gtc</guid>
<pubDate>Mon, 23 Feb 2026 13:00:00 GMT</pubDate>
<description>Salt Lake City, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will be featured in HighRes’ Lightning Talk at the NVIDIA GTC AI Conference & Expo happening March 16-19 in San Jose. Moderated by Stacie Calad-Thomson, Business Development Lead for Healthcare and Life Sciences at NVIDIA, the talk, “AI Agents, Robotics, and Digital Twins: The Full Stack of Self-Driving Labs and Bioma</description>
</item>
<item>
<title>Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25</title>
<link>https://6ix.com/company/recursion-pharmaceuticals-inc/news/recursion-to-report-fourth-quarter-and-full-year-2025-business-updates-and-financial-results-on-february-25</link>
<guid isPermaLink="true">https://6ix.com/company/recursion-pharmaceuticals-inc/news/recursion-to-report-fourth-quarter-and-full-year-2025-business-updates-and-financial-results-on-february-25</guid>
<pubDate>Wed, 18 Feb 2026 13:30:00 GMT</pubDate>
<description>Company to host public (L)earnings call on February 25 at 8:00 am ET / 6:00 am MT / 1:00 pm GMTSalt Lake City, UT, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, before the open of the financial markets. Recursion will host a (L)earnings Call on Februa</description>
</item>
<item>
<title>Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules</title>
<link>https://6ix.com/company/recursion-pharmaceuticals-inc/news/recursion-reports-grant-inducement-awards-125900157</link>
<guid isPermaLink="true">https://6ix.com/company/recursion-pharmaceuticals-inc/news/recursion-reports-grant-inducement-awards-125900157</guid>
<pubDate>Thu, 12 Feb 2026 12:59:00 GMT</pubDate>
<description>Salt Lake City, Utah, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, 2026, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 820,431 shares of its class A common stock in the aggregate to 17 new employees under Recursion's 2024 Inducement Equity Incentive Plan (the “2024 Plan”). Eac</description>
</item>
<item>
<title>Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/recursion-pharmaceuticals-inc/news/recursion-present-44th-annual-jp-morgan-healthcare-conference-2026-01-06</link>
<guid isPermaLink="true">https://6ix.com/company/recursion-pharmaceuticals-inc/news/recursion-present-44th-annual-jp-morgan-healthcare-conference-2026-01-06</guid>
<pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
<description>Salt Lake City, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve</description>
</item>
<item>
<title>Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks</title>
<link>https://6ix.com/company/recursion-pharmaceuticals-inc/news/positive-phase-1b-2-results-ongoing-rec-4881-tupelo-trial-demonstrate-rapid-and-0</link>
<guid isPermaLink="true">https://6ix.com/company/recursion-pharmaceuticals-inc/news/positive-phase-1b-2-results-ongoing-rec-4881-tupelo-trial-demonstrate-rapid-and-0</guid>
<pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
<description>REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after</description>
</item>
<item>
<title>Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025</title>
<link>https://6ix.com/company/recursion-pharmaceuticals-inc/news/recursion-announces-webinar-upcoming-clinical-data-readout-tupelo-phase-1b-2-trial</link>
<guid isPermaLink="true">https://6ix.com/company/recursion-pharmaceuticals-inc/news/recursion-announces-webinar-upcoming-clinical-data-readout-tupelo-phase-1b-2-trial</guid>
<pubDate>Mon, 01 Dec 2025 05:00:00 GMT</pubDate>
<description>Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve</description>
</item>
<item>
<title>Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/recursion-pharmaceuticals-inc/news/recursion-reports-third-quarter-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/recursion-pharmaceuticals-inc/news/recursion-reports-third-quarter-2025-financial-results-and-provides-business-update</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map designed to</description>
</item>
<item>
<title>Recursion Announces CEO Transition Plan to Drive Next Phase of Growth</title>
<link>https://6ix.com/company/recursion-pharmaceuticals-inc/news/recursion-announces-ceo-transition-plan-drive-next-phase-growth-2025-11-05</link>
<guid isPermaLink="true">https://6ix.com/company/recursion-pharmaceuticals-inc/news/recursion-announces-ceo-transition-plan-drive-next-phase-growth-2025-11-05</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>Co-Founder and CEO Chris Gibson to Transition to Chairman of the Board; Najat Khan to be named Chief Executive Officer and President Salt Lake City, Utah,</description>
</item>
<item>
<title>Recursion to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/recursion-pharmaceuticals-inc/news/recursion-participate-upcoming-investor-conferences-2025-11-04</link>
<guid isPermaLink="true">https://6ix.com/company/recursion-pharmaceuticals-inc/news/recursion-participate-upcoming-investor-conferences-2025-11-04</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>Salt Lake City, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve</description>
</item>
<item>
<title>Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th</title>
<link>https://6ix.com/company/recursion-pharmaceuticals-inc/news/recursion-report-third-quarter-2025-business-updates-and-financial-results-november</link>
<guid isPermaLink="true">https://6ix.com/company/recursion-pharmaceuticals-inc/news/recursion-report-third-quarter-2025-business-updates-and-financial-results-november</guid>
<pubDate>Tue, 28 Oct 2025 04:00:00 GMT</pubDate>
<description>Company to host public (L)earnings call on November 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMT Salt Lake City, UT, Oct. 28, 2025 (GLOBE NEWSWIRE) --</description>
</item>
<item>
<title>Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/recursion-pharmaceuticals-inc/news/rallybio-reports-second-quarter-2025-financial-results-and-provides-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/recursion-pharmaceuticals-inc/news/rallybio-reports-second-quarter-2025-financial-results-and-provides-business-updates</guid>
<pubDate>Thu, 07 Aug 2025 12:00:00 GMT</pubDate>
<description>NEW HAVEN, Conn., August 07, 2025--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported financial results for the second quarter ended June 30, 2025, and provided an update on recent company developments.</description>
</item>
<item>
<title>Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/recursion-pharmaceuticals-inc/news/recursion-reports-second-quarter-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/recursion-pharmaceuticals-inc/news/recursion-reports-second-quarter-2025-financial-results-and-provides-business-update</guid>
<pubDate>Tue, 05 Aug 2025 04:00:00 GMT</pubDate>
<description>Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and</description>
</item>
<item>
<title>Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th</title>
<link>https://6ix.com/company/recursion-pharmaceuticals-inc/news/recursion-report-second-quarter-2025-business-updates-and-financial-results-august</link>
<guid isPermaLink="true">https://6ix.com/company/recursion-pharmaceuticals-inc/news/recursion-report-second-quarter-2025-business-updates-and-financial-results-august</guid>
<pubDate>Tue, 29 Jul 2025 04:00:00 GMT</pubDate>
<description>Company to host public (L)earnings call on August 5th at 8:00 am ET / 6:00 am MT / 1:00 pm BST Salt Lake City, UT, July 29, 2025 (GLOBE NEWSWIRE) -- Recursion</description>
</item>
<item>
<title>Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals</title>
<link>https://6ix.com/company/recursion-pharmaceuticals-inc/news/rallybio-sells-interest-in-rev102-program-to-recursion-pharmaceuticals</link>
<guid isPermaLink="true">https://6ix.com/company/recursion-pharmaceuticals-inc/news/rallybio-sells-interest-in-rev102-program-to-recursion-pharmaceuticals</guid>
<pubDate>Tue, 08 Jul 2025 12:00:00 GMT</pubDate>
<description>NEW HAVEN, Conn., July 08, 2025--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that it has entered into a definitive agreement to sell its interest in REV102, an ENPP1 inhibitor in preclinical development for the treatment of patients with hypophosphatasia (HPP), to joint venture partner Recursion Pharmaceuticals for up to $25 million, including</description>
</item>
<item>
<title>Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia</title>
<link>https://6ix.com/company/recursion-pharmaceuticals-inc/news/recursion-acquires-full-rights-rev102-potential-first-class-oral-enpp1-inhibitor</link>
<guid isPermaLink="true">https://6ix.com/company/recursion-pharmaceuticals-inc/news/recursion-acquires-full-rights-rev102-potential-first-class-oral-enpp1-inhibitor</guid>
<pubDate>Tue, 08 Jul 2025 04:00:00 GMT</pubDate>
<description>Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve</description>
</item>
<item>
<title>MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy</title>
<link>https://6ix.com/company/recursion-pharmaceuticals-inc/news/mit-and-recursion-release-boltz-2-next-generation-ai-model-predict-binding-affinity</link>
<guid isPermaLink="true">https://6ix.com/company/recursion-pharmaceuticals-inc/news/mit-and-recursion-release-boltz-2-next-generation-ai-model-predict-binding-affinity</guid>
<pubDate>Fri, 06 Jun 2025 04:00:00 GMT</pubDate>
<description>Boltz-2 is the first biomolecular co-folding model to combine structure and binding affinity prediction, approaching the accuracy of physics-based free</description>
</item>
</channel>
</rss>